Chikungunya Vaccine, Recombinant (VIMKUNYA)
Chikungunya Vaccine, Recombinant is an FDA-licensed reference biologic from Bavarian Nordic A/S. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
VIMKUNYA Chikungunya Vaccine, Recombinant
Bavarian Nordic A/S
- Approved
- Feb 14, 2025
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Chikungunya Vaccine, Recombinant, in chronological order.
First licensure
Date Chikungunya Vaccine, Recombinant was first licensed by the FDA.
1 yr 4 mo ago
Reference approval
Approval date of the reference Chikungunya Vaccine, Recombinant product.
1 yr 4 mo ago
Reference exclusivity ends
12-year reference-product exclusivity under the BPCIA.
in 10 yr 10 mo
Frequently asked questions
Are there biosimilars approved for Chikungunya Vaccine, Recombinant (VIMKUNYA)?
No 351(k) biosimilars or interchangeable biosimilars referencing Chikungunya Vaccine, Recombinant are listed in the FDA Purple Book yet.
When does Chikungunya Vaccine, Recombinant (VIMKUNYA) lose reference-product exclusivity?
Chikungunya Vaccine, Recombinant's 12-year reference-product exclusivity under the BPCIA is listed in the FDA Purple Book as ending February 14, 2037.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.